RPS6KB1 and neoplasm: Similar to MK-2206 treated HT29 xenografts, significant tumour growth inhibition was also observed in PC3 xenografts after 2 doses (Day 1 and 3) of MK-2206 (120 mg/kg per dose) when compared with vehicle-treated controls (Fig. 2b) and AKT inhibition was confirmed by the reductions in the phosphorylation of P70S6K, RPS6 (Ser235/236), AKT (Ser473) and AKT (Thr308) (Supplementary Figure S6).